Preoperative Risk Assessment of Lymph Node Metastasis in cT1 Lung Cancer: A Retrospective Study from Eastern China
- PMID: 31886306
- PMCID: PMC6914921
- DOI: 10.1155/2019/6263249
Preoperative Risk Assessment of Lymph Node Metastasis in cT1 Lung Cancer: A Retrospective Study from Eastern China
Abstract
Background: Lymph node status of clinical T1 (diameter ≤ 3 cm) lung cancer largely affects the treatment strategies in the clinic. In order to assess lymph node status before operation, we aim to develop a noninvasive predictive model using preoperative clinical information.
Methods: We retrospectively reviewed 924 patients (development group) and 380 patients (validation group) of clinical T1 lung cancer. Univariate analysis followed by polytomous logistic regression was performed to estimate different risk factors of lymph node metastasis between N1 and N2 diseases. A predictive model of N2 metastasis was established with dichotomous logistic regression, externally validated and compared with previous models.
Results: Consolidation size and clinical N stage based on CT were two common independent risk factors for both N1 and N2 metastases, with different odds ratios. For N2 metastasis, we identified five independent predictors by dichotomous logistic regression: peripheral location, larger consolidation size, lymph node enlargement on CT, no smoking history, and higher levels of serum CEA. The model showed good calibration and discrimination ability in the development data, with the reasonable Hosmer-Lemeshow test (p = 0.839) and the area under the ROC being 0.931 (95% CI: 0.906-0.955). When externally validated, the model showed a great negative predictive value of 97.6% and the AUC of our model was better than other models.
Conclusion: In this study, we analyzed risk factors for both N1 and N2 metastases and built a predictive model to evaluate possibilities of N2 metastasis of clinical T1 lung cancers before the surgery. Our model will help to select patients with low probability of N2 metastasis and assist in clinical decision to further management.
Copyright © 2019 Chengyan Zhang et al.
Conflict of interest statement
The authors have no conflicts of interest to declare.
Figures
Similar articles
-
A prediction model for N2 disease in T1 non-small cell lung cancer.J Thorac Cardiovasc Surg. 2012 Dec;144(6):1360-4. doi: 10.1016/j.jtcvs.2012.06.050. Epub 2012 Jul 20. J Thorac Cardiovasc Surg. 2012. PMID: 22819364
-
A Texture Analysis-Based Prediction Model for Lymph Node Metastasis in Stage IA Lung Adenocarcinoma.Ann Thorac Surg. 2018 Jul;106(1):214-220. doi: 10.1016/j.athoracsur.2018.02.026. Epub 2018 Mar 14. Ann Thorac Surg. 2018. PMID: 29550204
-
[Risk factor analysis of mediastinal lymph node metastasis in non-small cell lung cancer patients and the strategy of mediastinoscopy prior to surgery].Zhonghua Zhong Liu Za Zhi. 2009 Jun;31(6):456-9. Zhonghua Zhong Liu Za Zhi. 2009. PMID: 19950559 Chinese.
-
[A clinical prediction model for N2 lymph node metastasis in clinical stage I non-small cell lung cancer].Beijing Da Xue Xue Bao Yi Xue Ban. 2015 Apr 18;47(2):295-301. Beijing Da Xue Xue Bao Yi Xue Ban. 2015. PMID: 25882948 Chinese.
-
Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.Eur J Cardiothorac Surg. 2009 Sep;36(3):440-5. doi: 10.1016/j.ejcts.2009.04.003. Epub 2009 May 22. Eur J Cardiothorac Surg. 2009. PMID: 19464906 Review.
Cited by
-
Lymph node metastasis and its risk factors in T1 lung adenocarcinoma.Thorac Cancer. 2023 Oct;14(30):2993-3000. doi: 10.1111/1759-7714.15088. Epub 2023 Sep 4. Thorac Cancer. 2023. PMID: 37667435 Free PMC article.
-
Blood-Derived Systemic Inflammation Markers and Risk of Nodal Failure in Stage Ia Non-Small Cell Lung Cancer: A Multicentric Study.J Clin Med. 2023 Jul 26;12(15):4912. doi: 10.3390/jcm12154912. J Clin Med. 2023. PMID: 37568316 Free PMC article.
-
Prognostic Roles of Glucose to Lymphocyte Ratio and Modified Glasgow Prognosis Score in Patients With Non-small Cell Lung Cancer.Front Nutr. 2022 May 10;9:871301. doi: 10.3389/fnut.2022.871301. eCollection 2022. Front Nutr. 2022. PMID: 35619963 Free PMC article.
-
Macrophage-Related SPP1 as a Potential Biomarker for Early Lymph Node Metastasis in Lung Adenocarcinoma.Front Cell Dev Biol. 2021 Sep 27;9:739358. doi: 10.3389/fcell.2021.739358. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34646827 Free PMC article.
-
Development and Validation of a Combined Model for Preoperative Prediction of Lymph Node Metastasis in Peripheral Lung Adenocarcinoma.Front Oncol. 2021 May 24;11:675877. doi: 10.3389/fonc.2021.675877. eCollection 2021. Front Oncol. 2021. PMID: 34109124 Free PMC article.
References
-
- van Meerkbeeck J., Van Schil P., Kramer G., et al. Pr5 A randomized trial of radical surgery (S) versus thoracicradiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941) Lung Cancer. 2005;49, article S4(Supplement 2) doi: 10.1016/S0169-5002(05)80131-X. - DOI
-
- Albain K. S., Swann R. S., Rusch V. R., et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309) Journal of Clinical Oncology. 2005;23(16):7014–7014. doi: 10.1200/jco.2005.23.16_suppl.7014. - DOI
-
- Betticher D. C., Hsu Schmitz S. F., Tötsch M., et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. Journal of Clinical Oncology. 2003;21(9):1752–1759. doi: 10.1200/JCO.2003.11.040. - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
